(untitled)Lacey M. Litchfield(Eli Lilly (United States))OncotargetApril 28, 202010.18632/oncotarget.v11i17Cited by 1SaveCiteExport RISWatch citationsRelated PapersAbemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.|Journal of Clinical Oncology|2024|75Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer|Oncotarget|2015|39